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Prevalence and distribution of cervical
high-risk human papillomavirus and
cytological abnormalities in women living
with HIV in Denmark – the SHADE
Kristina Thorsteinsson1,12* , Merete Storgaard2, Terese L. Katzenstein3,4, Steen Ladelund5,
Frederikke Falkencrone Rønsholt3, Isik Somuncu Johansen6, Gitte Pedersen7, Lailoma Hashemi8,
Lars Nørregård Nielsen9, Lisbeth Nilas4,10, Niels Obel3,4, Jesper Bonde11 and Anne-Mette Lebech1,4
Abstract
Background: Women living with HIV (WLWH) are at increased risk of persistent human papillomavirus (HPV)
infection, cervical dysplasia and cervical cancer compared with women from the general population (WGP). We
assessed the prevalence and distribution of cervical high-risk (hr) HPV infection and cytological abnormalities in
WLWH compared with WGP in Denmark. Predictors of HPV and cytological abnormalities were estimated in WLWH.
Methods: WLWH consecutively enrolled in the Study on HIV, cervical Abnormalities and infections in women in
Denmark (SHADE) in 2011 and were examined for cervical HPV and cytological abnormalities.
WLWH were matched on age and prior cytological findings with WGP from an earlier study. HIV demographics
were retrieved from the nationwide Danish HIV Cohort Study. Logistic regression was used to estimate predictors of
hrHPV and cytological abnormalities.
Results: Of 334 included WLWH 26.4 % were positive for hrHPV as opposed to 16.6 % WGP (p < 0.0001). WLWH had
a higher number of multiple infections (>1 h genotype present) (38.5 % versus 25.7 %, p = 0.030). Hr genotypes in
descending order of frequency were HPV58 (7.1 %), 52 (5.4 %), and 16 (4.8 %) in WLWH versus HPV16 (4.1 %), 52
(2.8 %) and 58 (2.4 %) in WGP. Predictors of hrHPV in WLWH were short duration of HAART (adjusted OR per year
0.90 (95 % CI 0.84-0.96)), AIDS prior to inclusion (adjusted OR 3.61 (95 % CI 1.75-7.46)), ≥5 lifetime sexual partners
(adjusted OR 2.20 (95 % CI 1.08-4.49)), sexual debut <16 years of age (adjusted OR 2.05 (95 % CI 1.03-4.10)) and
CD4 < 350 cells/μL (adjusted OR 2.53 (95 % CI 1.20-5.40)). Cytological abnormalities were prevalent in 10.4 % vs.
5.2 % (p = 0.0003) of WLWH and WGP. In WLWH with hrHPV, short duration of HAART predicted cervical dysplasia
(adjusted OR per year 0.83 (95 % CI 0.71-0.97)).
Conclusions: WLWH presented with more cervical hrHPV infections and cytological abnormalities, and a different
distribution of hrHPV genotypes compared with WGP. Cervical hrHPV and cytological abnormalities were predicted
by short duration of HAART.
Keywords: Women living with HIV, High-risk human papillomavirus, Cervical cytological abnormalities, HPV vaccine,
Highly active antiretroviral therapy
* Correspondence: Kristina.thorsteinsson@gmail.com
1Department of Infectious Diseases, Hvidovre, Copenhagen University
Hospital, Copenhagen, Denmark
12Department of Infectious Diseases, Hvidovre Hospital, Kettegaards Allé 30,
2650 Hvidovre, Denmark
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Thorsteinsson et al. BMC Cancer  (2016) 16:866 
DOI 10.1186/s12885-016-2881-1
Background
Human papillomavirus (HPV) is the most common
sexually transmitted disease (STD) [1] with a lifetime
prevalence of up to 80 % [2]. Essentially, all cases of
cervical cancer (CC) are associated with high-risk HPV
(hrHPV) [3] and worldwide approximately half a million
women develop CC each year [4]. Women living with
HIV (WLWH) are at increased risk of persistent HPV
infection, cervical dysplasia and CC compared with
women from the general population (WGP) [5–9].
Comprehensive data on the prevalence and distribu-
tion of HPV genotypes are informative in the planning
of HPV/CC screening tools and with the rollout of HPV
vaccines [10]. The hrHPV genotype distribution in
Denmark [11, 12] and worldwide is well described in
WGP and globally HPV16, 18, 52, 31, and 58 predomin-
ate [10, 13, 14]. Most studies suggest a different HPV
genotype distribution in WLWH with increased fre-
quency of non-16/18 HPV genotypes, which are not
targeted by the 2-and 4-valent HPV vaccines [8, 15, 16].
Though, immune reconstitution induced by highly
active antiretroviral therapy (HAART) might decrease
the prevalence of HPV and cervical dysplasia, the effect
of improved immunosurveillance remains controversial
[6, 7]. The increased longevity gained from HAART [17]
may increase risk of exposure to HPV and provide the
time required for progression to cancer.
Compared with other Western countries WGP in
Denmark have high incidences of HPV and CC [11, 18,
19]. However, the prevalence and distribution of cervical
HPV and dysplasia are unknown in WLWH in Denmark.
Denmark offers a unique setting for studies on HPV and
cervical dysplasia because of the well described HPV
genotype distribution in WGP in Denmark [11, 19] and
the possibility for linkage to nationwide registries on
HIV and cytology results.
The aim of the present study was to assess the preva-
lence and distribution of cervical hrHPV and cytological
abnormalities in WLWH in Denmark. Further, we aimed
at identifying predictors of hrHPV and cytological ab-
normalities in WLWH in a setting with free access to
CC screening, healthcare and HAART.
Methods
Setting
Denmark has a population of 5.6 million [20] and an esti-
mated HIV prevalence among adults of 0.1 % [21] - one-
fourth of these being women [22]. Medical care, including
HAART, is tax-paid and provided free-of-charge to all
people living with HIV (PLHIV). Treatment of HIV is
restricted to eight specialized centres, of which six (treat-
ing 97 % of Danish PLHIV) participated in the Study on
HIV, cervical Abnormalities and infections in women in
Denmark (SHADE) [23] (see below).
Cervical screening in Denmark
During the study period, The Danish National Board
of Health recommended that women aged 23–49
years received cervical cytological testing every three
years and women aged 50–65 years every five years
[24]. In HIV guidelines cervical cytology is recom-
mended twice the first year after HIV diagnosis and
annually thereafter [25].
The SHADE cohort
The SHADE cohort is a multicentre, prospective, obser-
vational cohort study of WLWH in Denmark. Study
procedures have been described previously [23]. In brief,
study participants were consecutively enrolled during
their outpatient visits from 1 February 2011 to 1 February
2012. Inclusion criteria were HIV-1 infection and ≥18 years
of age. Exclusion criteria were prior hysterectomy, preg-
nancy, alcohol and/or drug abuse impeding adherence to
the protocol.
Interview survey
At entry, an interview including tobacco use, age at
sexual debut, lifetime sexual partners, prior condyloma,
HPV vaccination status, and contraceptive use etc. was
performed. The EpiData Entry program was used for
double manual data entry [26].
Registries
Civil Registration System (CRS)
The CRS is a national registry of all Danish residents
[27]. A 10-digit personal identification number (PIN) is
assigned to each individual at birth or immigration. The
PIN was used to link the SHADE cohort, the Danish
HIV Cohort Study (DHCS) and the The Danish Pathology
Data Bank (DPDB).
Danish HIV cohort study
The DHCS is a prospective, observational, nationwide,
multicentre cohort study of all PLHIV seen at the
Danish HIV clinics since 1 January 1995. The cohort has
been described in detail elsewhere [22].
The Danish Pathology Data Bank (DPDB)
The DPDB contains nationwide records of all pathology
specimens [28]. Cytology samples prior to inclusion were
retrieved to assess screening history and cytology results
using the Systemized Nomenclature of Medicine
(SNOMED) code of cervix uteri: T8x2*, T8x3* and T83*.
Data from the general population (the Horizon Study)
Anonymised data on HPV (from the CLART assay) and
cytology results from WGP included in the Danish Horizon
Study, Copenhagen, Denmark, were retrieved from the
authors [11].
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Cytology
Cytological evaluation of SurePath samples was under-
taken at Department of Pathology, Hvidovre, Copenhagen
University Hospital (HVH). The outcomes were reported
using the Bethesda 2001 system [29] and classified as nor-
mal, atypical cells of undetermined significance (ASCUS),
low-grade squamous intraepithelial lesions (LSIL), or
high-grade squamous intraepithelial lesions (HSIL) includ-
ing atypical squamous cells - cannot exclude HSIL (ASC-
H), atypical glandular cells (AGC) and adenocarcinoma in
situ (AIS), and finally squamous cell-and adenocarcinoma.
HPV DNA testing
Cervical samples were examined by the CLART HPV2
assay (Genomica, Madrid, Spain) at Department of Path-
ology, HVH. PCR amplification of genotype specific
HPV L1 fragments from 35 individual HPV genotypes
was performed including 13 hrHPV: HPV16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, and 68 [11]. Samples with
invalid outcomes were retested. The second result was
considered definitive [11].
Statistical analysis
Continuous variables were summarized as median and
interquartile ranges (IQR) or mean and ranges and com-
pared using the Wilcoxon rank sum test. Categorical
variables were reported as counts and percentages and
compared using the chi-square test or Fisher’s exact test.
For comparison of HPV status, genotype distribution
and cytology results study participants were matched 1:5
to WGP on prior screening history in accordance with
the algorithm used in the Horizon study [11] and age
with a tolerance of 2 years (choosing the 5 WGP numer-
ically closest to the participant’s age).
Univariate and multiple logistic regression analyses
were used for identifying predictors of hrHPV expressed
as odds ratios (OR) and 95 % confidence intervals (CI).
Nine candidate predictor variables were chosen a
priori due to current knowledge on risk factors of
HPV [6, 30, 31]; age (18–29, 30–50 and >50 years of
age), race, age at sexual debut (<16 versus ≥ 16 years
of age), HAART duration (years on HAART), AIDS
prior to inclusion, smoking status, number of lifetime
sexual partners (<5 versus ≥ 5), use of hormonal contra-
ceptives, and CD4 count at inclusion (<200, ≥200-349
and ≥350 cells/μL).
Predictors of ASCUS or worse (ASCUS+) were esti-
mated by including the aforementioned variables, pres-
ence of cervical hrHPV and adherence to the general
population CC screening program in the analysis. A
subgroup analysis was performed in WLWH with
ASCUS+ and cervical hrHPV only.
Duration of HAART, AIDS prior to inclusion and CD4
count are dependent covariates and where calculated
using two models: A model where all variables but CD4
at inclusion was included and a model where duration of
HAART and AIDS prior to inclusion were replaced by
CD4. We only presented the OR of the CD4 count from
the second model.
To account for multiple testing when comparing the
distribution of genotypes, we applied Bonferoni cor-
rection. Therefore, in analyses of the 13 hrHPV genotypes
p-values smaller than 0.05:13 (p < 0.0038) were considered
statistically significant. In the remaining analyses p-values
<0.05 were considered statistically significant. For category
variables with more than two outcome categories (df > 1),
we controlled for repeated testing by estimating the com-
bined p-value. Individuals with missing explanatory values
were excluded from the multiple regression analyses. The
validity of the model was tested using the Hosmer and
Lemeshow Goodness-of-Fit Test.
SAS statistical software version 9.3 (SAS Institute Inc.,
Cary, NC, USA) was used for data analysis. The match-
ing of study participants and the HPV genotype distribu-
tion figures were performed in R 3.2.0 [32].
Results
Characteristics of the cohort
A total of 334 of the 1392 eligible WLWH in Denmark
(in the DHCS) were included. At inclusion, median age
and duration of HIV were 42.5 (IQR 36.8-48.3) and 11.3
(IQR 5.9-16.9) years (Table 1). Compared with WLWH
from the DHCS not included, WLWH in SHADE were
more likely to be sexually infected with HIV (p = 0.0015),
have higher CD4 counts (p = 0.012), and increased prob-
abilities of being on HAART with a suppressed viral load
(p = 0.0042). Moreover, they had a higher uptake of both
the annual HIV-and general population CC screening
program (p < 0.0001 and p < 0.0001) and a higher
probability of the latest cytology result being normal
(p < 0.0001) (Table 1).
HPV prevalence
Of 334 participants, 326 (97.6 %) had a cervical swab
performed. Of these 295 (90.5 %) yielded sufficient DNA
for analysis and were matched at 1:5 with 1475 WGP
from the Horizon study (Fig. 1).
Overall HPV prevalence was higher in WLWH versus
WGP (26.4 % versus 16.6 %, p < 0.0001) (Table 2). Fur-
ther, WLWH had a higher number of multiple infections
with more genotypes diagnosed per sample (p = 0.030
and p = 0.047) (Table 2). Median age of WGP was due to
the age matching criteria close to that of WLWH (stated
above); 43.0 (IQR 37.0-49.0) years. The hrHPV preva-
lence according to age is shown in Fig. 2.
More WGP would have been protected by the 4-valent
HPV vaccine than WLWH (p = 0.030), whereas both
groups of women would receive a similar degree of
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Table 1 Characteristics of included and not included women living with HIV (WLWH) in Denmark from the Danish HIV Cohort
Study (DHCS)
WLWH
included in the study
WLWH
not included in the study
p-value
Number of individuals 334 (24.0) 1,058 (76.0) NA
Follow-up (years), median (IQR) 11.3 (5.9-16.9) 10.6 (5.5-15.9) 0.097
Follow-up time, total (person-years) 3,853 11,183 NA
Age at inclusion (years), median (IQR) 42.5 (36.8-48.3) 42.0 (35.5-48.2) 0.22
Race, n(%)
White 141 (42.6) 398 (39.5) 0.041a
Asian 44 (13.3) 114 (11.3)
Black 143 (43.2) 461 (45.7)
Other 3 (0.9) 35 (3.5)
(missing) (3) (50)
Place of HIV transmission, n(%)
Denmark 114 (37.8) 326 (34.8) 0.11
Europe + US 27 (8.9) 77 (8.2)
Africa 128 (42.4) 416 (44.4)
Asia 33 (10.9) 101 (10.8)
Other 0 (0) 17 (1.8)
(missing) (32) (121)
Mode of transmission, n(%)
Heterosexual 294 (91.6) 799 (83.6) 0.0015
IDU 16 (5.0) 106 (11.1)
Other 11 (3.4) 51 (5.3)
(missing) (13) (102)
Age at sexual debut (years),
mean (range) 17.3 (6–37) -b NA
Lifetime sexual partners, n(%)
< 5 99 (29.6) -b NA
5–14 135 (40.4)
15–25 45 (13.5)
> 25 53 (15.9)
Does not wish to respond 2 (0.6)
(missing) (0)
CD4 count at inclusion (cells/μL), n(%)
< 200 12 (3.9) 79 (9.1) 0.012
200–350 51 (16.5) 138 (15.9)
> 350 247 (79.7) 650 (75.0)
(missing) (24) (191)
HAART at inclusion, n(%)
Yes 317 (94.9) 866 (81.8) <0.0001
No 17 (5.1) 192 (18.2)
(missing) (0) (0)
On HAART with
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protection from the 9-valent HPV vaccine based upon
their HPV genotype distribution (p = 0.14) (Table 2).
HPV genotype distribution
Figure 3 shows the prevalence of hrHPV genotypes with
respect to race: i) overall, ii) in WLWH and WGP with
normal cytological findings, and iii) WLWH and WGP
with ASCUS+. Overall, the six most frequent high-risk
genotypes in WLWH were HPV58 (n = 21, 7.1 %), 52
(n = 16, 5.4 %), 16 (n = 14, 4.8 %), 51 (n = 12, 4.1 %),
18 (n = 10, 3.4 %) and 33 (n = 10, 3.4 %) versus 16 (n = 60,
4.1 %), 52 (n = 41, 2.8 %), 58 (n = 35, 2.4 %), 31 (n = 32,
2.2 %), 51 (n = 28, 1.9 %) and 33 (n = 26, 1.8) in WGP
(Fig. 3, Additional file 1: Table S1).
HPV genotype distribution according to race
There was no difference in prevalence of hrHPV in
WLWH of White, Asian and Black race (26.6 %, 16.2 %
and 29.0, (p = 0.30)). We compared genotype distribution
in WLWH of different races and found that Black
WLWH had a higher risk of HPV58 and 56 compared
with WGP (p < 0.0001 and p = 0.0023) (Fig. 3), while no
significant differences in hrHPV genotype distribution
were found between White and Asian WLWH com-
pared with WGP (Fig. 3).
HPV genotype distribution in women with normal
cytology
In women with normal cytology the hrHPV preva-
lence was 22.0 % in WLWH versus 13.0 % in WGP
(p = 0.0004). HPV58 (n = 13, 5.1 %), 52 (n = 11, 4.3 %),
51 (n = 8, 3.1 %) versus HPV16 (n = 49, 3.5 %), 58 (n = 30,
2.2 %) and 52 (n = 30, 2.2 %) predominated in
WLWH and WGP, respectively (Fig. 3, Additional
file 2: Table S2).
HPV genotype distribution in women presenting with
ASCUS+
In WLWH and WGP with ASCUS+ 61.8 % versus
49.0 % were hrHPV-positive (p = 0.25).
Table 1 Characteristics of included and not included women living with HIV (WLWH) in Denmark from the Danish HIV Cohort
Study (DHCS) (Continued)
HIV RNA < 40 copies/mL, n(%)
Yes 250 (83.6) 576 (75.5) 0.0042
No 49 (16.4) 187 (24.5)
(missing) (18) (103)
Cervical cytology within the past 1 year, n(%)c
Yes 124 (37.1) 225 (21.3) <0.0001
No 210 (62.9) 833 (78.7)
(missing) (0) (0)
Cervical cytology within the past 3/5 years – depending on age for women age 23–65 years, n(%)d
Yes 227 (67.7) 429 (40.6) <0.0001
No 96 (28.7) 555 (52.5)
Outside target age group 11 (3.3) 74 (7.0)
(missing) (0) (0)
Last cytology result, n(%)
Normal 242 (72.5) 513 (48.5) <0.0001
Abnormal 9 (2.7) 21 (2.0)
No prior cytology obtained 83 (24.9) 524 (49.5)
HPV vaccination prior to inclusion, n(%)
Yes (4-valent HPV vaccine) 4 (1.2) -b NA
Yes (2-valent HPV vaccine) 0 (0)
Yes (do not know name of vaccine) 1 (0.3)
No 329 (98.5)
(missing) (0)
IDU intravenous drug user, NA not applicable, HAART Highly active antiretroviral therapy, HPV Human papillomavirus
aThere was no difference in distribution of race between groups if the category “other” was removed from the “Race” variable (p = 0.45), bNo information
available, cAs recommended in women living with HIV (we studied the past year + a 3-month grace period), dAs recommended in the general population, where
women aged 23–49 years were invited for cervical cancer screening every third year and women aged 50–65 years every fifth year (we studied the past
3/5 years + a 3-month grace period)
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Table 2 Prevalence of high-risk human papillomavirus (HPV) in women with sufficient DNA for analyses in women living with HIV
compared to women matched (1:5) on prior screening history and age from the general Danish population
Women living with HIV
295
Women from the general population
1,475
p-value
High-risk HPV positive, n(%)
Yes 78 (26.4) 245 (16.6) <0.0001
No 217 (73.6) 1,230 (83.4)
Number of genotypes, mean (range) 1.54 (1–4) 1.38 (1–5) 0.047
Number of infections, n(%)
Single 48 (61.5) 182 (74.3) 0.030
Multiple (>1) 30 (38.5) 63 (25.7)
All high-risk genotypes present targeted by the 4-valent HPV vaccinea, n(% of the HPV positive patients)
Yes 8 (10.3) 52 (21.2) 0.030
No 70 (89.7) 193 (78.8)
All high-risk genotypes present targeted by the 9-valent vaccineb, n(% of the HPV positive patients)
Yes 42 (53.9) 155 (63.3) 0.14
No 36 (46.1) 90 (36.7)
Presence of ≥1 high-risk genotypes targeted by the 4-valent vaccinea, n(% of the HPV positive patients)
Yes 21 (26.9) 76 (31.0) 0.49
No 57 (73.1) 169 (69.0)
Presence of ≥1 high-risk genotypes targeted by the 9-valent vaccineb, n(% of the HPV positive patients)
Yes 61 (78.2) 194 (79.2) 0.85
No 17 (21.8) 51 (20.8)
aTargeting HPV6, HPV11, HPV16 and HPV18. HPV6 and HPV11 are low-risk genotypes and not included in this analysis
bTargeting HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58. HPV6, and HPV11 are low-risk genotypes and not included in this analysis
Fig. 1 Flowchart of women living with HIV (WLWH) from the SHADE cohort and women from the general population (WGP) from the Horizon
study matched 1:5 on prior screening history and age
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Distribution of genotypes in descending order in
WLWH and WGP presenting with ASCUS+ were HPV58
(n = 8, 23.5 %), 16 (n = 7, 20.6 %) and 56 (n = 5, 14.7 %)
versus HPV52 (n = 11, 14.1 %), 16 (n = 10, 12.8 %) and 45
(n = 9, 11.5 %) (Fig. 3, Additional file 3: Table S3).
Predictors of HPV
Short duration of HAART (adjusted OR per year 0.90 (95
% CI 0.84-0.96)), AIDS prior to inclusion (adjusted OR
3.61 (95 % CI 1.75-7.46)), ≥5 lifetime sexual partners
(adjusted OR 2.20 (95 % CI 1.08-4.49)), sexual debut
<16 years of age (adjusted OR 2.05 (95 % CI 1.03-4.10))
and CD4 < 350 cells/μL (adjusted OR 2.53 (95 % CI
1.20-5.40)) predicted prevalent hrHPV (Table 3).
Cervical cytological abnormalities
Five (1.5 %) of the 332 cytology samples received from
WLWH were inadequate for evaluation leaving 327 for in-
terpretation. These were matched with cytology results
from 1635 WGP (Fig. 1). ASCUS+ was prevalent in 34
(10.4 %) versus 85 (5.2 %) WLWH and WGP, (p = 0.0003).
Cytological abnormalities in WLWH and WGP were
distributed as follows: ASCUS: 8 (2.5 %) versus 42 (2.6 %),
(p = 0.90); LSIL: 20 (6.1 %) versus 23 (1.4 %), (p < 0.0001)
and HSIL: 6 (1.8 %) versus 20 (1.2 %), (p = 0.38). No
WLWH or WGP presented with carcinoma.
Predictors of cytological abnormalities
HrHPV predicted ASCUS+ (adjusted OR 6.91 (95 % CI
2.91-16.42)) (Additional file 4: Table S4). However, in
the subgroup of WLWH with hrHPV short duration of
HAART predicted ASCUS+ (adjusted OR 0.83 (95 % CI
0.71-0.97)) (Additional file 5: Table S5).
In all adjusted analyses we checked the effect of miss-
ing values on outcome by adding an extra category with
missing values. This had no impact on the estimates.
Discussion
In this multicentre, cross-sectional cohort study of
WLWH in Denmark, we found a higher prevalence of cer-
vical hrHPV in WLWH compared with WGP matched on
prior screening history and age. Further, WLWH had a
higher number of hrHPV genotypes and more carried
multiple hrHPV infections. Presence of ≥1 genotypes
covered by the 9-valent HPV vaccine was higher in
WLWH and a higher number of WGP had all present
genotypes covered by the 4-valent HPV vaccine.
WLWH had a different distribution of hrHPV genotypes
and this difference was mainly attributed to WLWH of
Black race. There was a higher risk of ASCUS+ in
WLWH, due to a higher prevalence of LSIL. Finally, cer-
vical HPV and ASCUS+ were predicted by short duration
of HAART.
Fig. 2 Prevalence of high-risk human papillomavirus (HPV) according to age group in women living with HIV (WLWH) and women from the
general population (WGP)
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Fig. 3 (See legend on next page.)
Thorsteinsson et al. BMC Cancer  (2016) 16:866 Page 8 of 13
HPV prevalence
Prevalent HPV infection is dependent on age with a
peak prevalence in women in the early 20s followed by a
steady decline and a second, but smaller peak in women
≥45 years of age attributed to either new acquisition or
viral persistence [2, 14]. Therefore, we chose to match
WLWH and WGP on age and prior cytology/histology
results. The overall hrHPV prevalence in WLWH of
26.4 % was lower than the hrHPV prevalence found in
the European MACH-1 collaborative group of WLWH
with a prevalence close to 50 % [15], however partici-
pants in the MACH study were younger (median age: 35
versus 42.5 years), less likely to be on HAART (69.7 %
versus 94.9 %) and a different assay (Hybrid Capture II)
was used for HPV detection. On a global scale the high-
est prevalence of HPV in WGP with normal cytological
findings is found in Africa (24 %) [14]. Though, the over-
all hrHPV prevalence was highest in WLWH of Black
race, this difference was not significant.
HPV genotype distribution
Studies of WGP across all continents have repeatedly
identified hrHPV16 and 18 - accounting for about 70 %
of all CCs [2, 6] – to be among the most prevalent [8].
In agreement with others we found HPV58 and 52 to be
prevailing in WLWH [8, 16]. Though, the numbers were
small, this higher risk of HPV58 was mainly carried by
women of Black race, as no significant difference in
genotype distribution, was detected when comparing
WGP with WLWH of White and Asian race. While the
2-and 4-valent HPV vaccines are anticipated to reduce
the burden of HPV-related cancers in WGP [13], the
impact of these HPV vaccines in WLWH is less clear.
More than 20 % of WGP had all genotypes present
covered by the 4-valent HPV vaccine, whereas only
one-tenth of genotypes were accounted for amongst
WLWH. The novel 9-valent HPV-vaccine targeting
HPV6, 11, 16, 18, 31, 33, 45, 52, and 58 has the po-
tential to prevent about 90 % of CC cases in WGP if
administered before sexual onset [33] might be better
suited for the HIV population.
Predictors of HPV
The molecular mechanisms leading to the increased
risk of HPV in PLHIV are poorly understood [34].
Tugizov et al. suggested that HIV-proteins enable ini-
tial HPV infection by disrupting the epithelial tight
junctions [34]. Moreover, immune defects associated
with HIV infection probably contribute to the HPV
pathogenesis by preventing spontaneous clearance of
HPV [6]. A recent study found that in WLWH every
month on HAART reduced the detection risk of any
cervical HPV infection by 9 % [30]. Likewise, short
duration of HAART predicted HPV in the current
study. Moreover, sexual behavior such as early sexual
debut and ≥5 lifetime sexual partners predicted preva-
lent HPV and so did variables associated with a com-
promised immune system such as CD4 < 350 cells/μL
and AIDS prior to inclusion.
Cytological abnormalities
Overall, WLWH had more cytological abnormalities,
due to a higher prevalence of LSIL. A higher prevalence
of LSIL, but not ASCUS and HSIL, in WLWH is also
reported by others [35]. Most LSILs are transient and
resolve within 1–2 years [36], and are most often not
treated according to current Danish guidelines. A high
proportion of WLWH included and not included in the
study; 28.7 % and 52.5 %, had not been screened for CC
in the preceding 3 to 5 years. We have previously
assessed low screening attendance in this cohort of
WLWH and support the idea of cytology as part of an
annual medical HIV review, integration of HIV care and
cervical screening in a single clinic setting and targeted
public health messages aimed at health care profes-
sionals at HIV centres, general practitioners and WLWH
[37]. However, the low screening attendance does not
explain differences in cytological abnormalities between
WLWH and WGP, since women were matched on prior
screening history.
Predictors of cervical dysplasia
Predictors of cervical dysplasia and CC are those also
associated with HPV infection such as smoking, early
sexual debut, number of lifetime sexual partners, hormo-
nal contraceptives and STDs other than HPV [6, 7]. We
have earlier reported that only a very few of WLWH in
SHADE presented with STDs other than HPV [23] and
therefore this variable was not adjusted for. Not surpris-
ingly, hrHPV predicted ASCUS+. Since hrHPV causes
most cases of dysplasia and basically all cases of CC [6],
this variable could blur the effect of other covariates. We
therefore performed a sensitivity analysis in WLWH
with hrHPV, and in consistence with our findings
regarding HPV we found that short duration of HAART
predicted ASCUS+.
(See figure on previous page.)
Fig. 3 Cervical high-risk human papillomavirus (HPV) genotype distribution in women living with HIV (WLWH) compared to women from the
general population (WGP); i) overall, ii) in women with normal cervical cytology, and iii) women with atypical cells of undetermined significance
(ASCUS) or worse. Distribution is presented i) overall, ii) comparing WGP to WLWH of White race, iii) comparing WGP to WLWH of Black race and
iv) comparing WGP to WLWH of Asian race. Please notice the different scale on the y-axis in the “ASCUS or worse” plots
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Table 3 Unadjusted and adjusted odds ratios for predictors of cervical high-risk human papillomavirus (HPV) infection in women
living with HIV with sufficient DNA for HPV analysis (n = 295)
Predictors of HPVa HPV-positive group
(n = 78)
HPV-negative group
(n = 151)
Unadjusted odds ratios p-value Adjusted odds ratiosb p-value
Age at 1 February 2011 (inclusion), n(%)
18-29 years 9 (11.5) 9 (4.2) 1.00 - 1.00 -
30-50 years 51 (65.4) 161 (74.2) 0.32 (0.12-0.84) 0.02 0.43 (0.14-1.33) 0.14
> 50 years 18 (23.1) 47 (21.7) 0.38 (0.13-1.12) 0.08 0.51 (0.13-1.92) 0.32
(missing) 0 (0) (0)
Combined p-value 0.068 0.32
Race, n(%)
White 34 (44.7) 94 (44.1) 1.00 - 1.00 -
Asian 6 (7.9) 31 (14.6) 0.54 (0.21-1.40) 0.20 0.67 (0.23-1.92) 0.46
Black 36 (47.4) 88 (41.3) 1.13 (0.65-1.96) 0.66 0.38 (0.67-2.87) 0.38
(missing) (2) (4) - -
Combined p-value 0.31 0.35
Sexual debut, n(%)
≥ 16 years of age 51 (65.4) 160 (73.7) 1.00 - 1.00 -
< 16 years of age 27 (34.6) 57 (26.3) 1.49 (0.85-2.59) 0.16 2.05 (1.03-4.10) 0.042
(missing) (0) (0) -
HAART duration, (years)
Median (IQR) 4.6 (2.0-10.4) 8.8 (4.6-12.2) 0.91 (0.86-0.96) 0.0013 0.90 (0.84-0.96) 0.0011
(missing) (2) (9)
AIDS prior to inclusion, n(%)
No 55 (71.4) 191 (88.4) 1.00 - 1.00 -
Yes 22 (28.6) 25 (11.6) 0.33 (0.17-0.63) 0.0007 3.61 (1.75-7.46) 0.0005
(missing) (1) (1)
Smoking status, n(%)
Current smoker/Ex-smoker 33 (42.3) 92 (42.4) 1.00 - 1.00 -
Never smoker 45 (57.7) 125 (57.6) 1.00 (0.59-1.69) 0.99 1.31 (0.65-2.63) 0.45
(missing) (0) (0)
Number of lifetime sexual partners at inclusion, n(%)
< 5 36 (25.0) 54 (36.0) 1.00 - 1.00 -
≥ 5 108 (75.0) 96 (64.0) 1.83 (1.00-3.36) 0.05 2.20 (1.08-4.49) 0.03
(missing) (0) (1)
Use of hormonal contraceptives,
n(%) 12 (8.3) 9 (6.0) 1.00 - 1.00 -
Yes 132 (91.7) 142 (94.0) 0.89 (0.33-2.38) 0.82 1.29 (0.40-4.10) 0.67
No (0) (0)
(missing)
CD4 count at inclusion (cells/μL),
> 350 45 (69.2) 173 (83.2) 1.00 - 1.00 -
200-350 15 (23.1) 28 (13.5) 2.06 (1.02-4.18) 0.045 2.53 (1.20-5.40) 0.015
< 200 5 (7.7) 7 (3.4) 2.75 (0.83-9.06) 0.10 2.70 (0.78-9.33) 0.12
(missing) (13) (9)
Combined p-value 0.0496 0.023
HAART = Highly active antiretroviral therapy
aTwo models are shown in the table: Age, race, sexual debut, smoking status, number of lifetime sexual partners and use of hormonal contraceptives were
included in both models, whereas HAART duration and AIDS prior to inclusion were included in the first model and replaced by CD4 at inclusion inthe second
model, We only presented the ORs of the CD4 count from the second model, bThe validity of the model was tested using the Hosmer and Lemeshow
Goodness-of-Fit Test
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Strengths and limitations
We have a very well-described cohort due to the DHCS
and DPDB and were able to match on prior cytological
outcomes. Compared to other Western countries Danish
women represent a CC high-risk population [18], there-
fore comparison to WGP is essential in interpretation of
results.
Possible limitations are that WLWH included in
SHADE were more likely to comply with CC screening
programs and to have a previous normal cytology result.
Therefore estimates regarding cytological abnormalities
in WLWH might be conservative. The effect of HAART
duration can be confounded by other time-scales such
as duration of HIV. Moreover, racial origin of the WGP
group was not available for direct comparison to the
SHADE cohort. Furthermore, a higher number of inad-
equate HPV samples were collected in the present study
compared to ordinary CC screening samples included in
the Horizon study, probably as a consequence of sam-
pling by personnel less trained in gynecological routines.
Finally, this is a cross-sectional study giving information
on HPV infection at the time of one single sampling.
The limitation in this design is that without previous or
subsequent sampling results, any HPV infection ob-
served may be a transient infection.
Conclusions
WLWH had a higher risk of being cervical hrHPV posi-
tive, a higher frequency of multiple infections, a different
genotype distribution and more cytological abnormalities
than WGP. Cervical HPV and ASCUS+ were predicted by
short duration of HAART.
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